MTVA Stock Forecast & Price Target

MetaVia is positioned for strong growth with two promising programs focused on MASH and obesity. Based on a risk-adjusted NPV valuation model, the company has an estimated value of $20 per share, reflecting potential revenue from both DA-1726 and DA-1241. Key risks to this valuation include disappointing data from ongoing studies, potential collaboration delays, and intellectual property opposition. Going forward, investors will be watching for successful titration and deepening weight loss in DA-1726's Phase 1 Part 3 program, as well as scheduling and completing an FDA end-of-Phase 2 meeting for vanoglipel. With $13.7M in cash and a clear runway into 4Q26, MetaVia appears to be well-funded, but clean execution is crucial to maintain investor confidence.

MetaVia is facing high expectations from investors for its upcoming 4Q26 Phase 1 readout for DA-1726, with a focus on whether the drug's efficacy can match its tolerability and liver/metabolic signals at increased doses. The upcoming presentations at ADA and EASL could significantly de-risk the readout if they confirm the prior positive signals, and the preclinical posters exploring combinations may attract more attention to the company's potential in the market. However, it is worth noting that MetaVia has a relatively high amount of spending in sales and marketing, which may put pressure on their financials in the short term.